Advertisement
IMDX vs NEPH
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IMDX is a StrongBuy and NEPH is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
IMDX’s FA Score shows that 0 FA rating(s) are green whileNEPH’s FA Score has 0 green FA rating(s).
- IMDX’s FA Score: 0 green, 5 red.
- NEPH’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
IMDX’s TA Score shows that 4 TA indicator(s) are bullish while NEPH’s TA Score has 5 bullish TA indicator(s).
- IMDX’s TA Score: 4 bullish, 6 bearish.
- NEPH’s TA Score: 5 bullish, 3 bearish.
Price Growth
IMDX (@Medical Specialties) experienced а -18.62% price change this week, while NEPH (@Pharmaceuticals: Other) price change was +1.13% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was -3.19%. For the same industry, the average monthly price growth was +9.26%, and the average quarterly price growth was +1.11%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -2.39%. For the same industry, the average monthly price growth was +7.29%, and the average quarterly price growth was -8.66%.
Reported Earning Dates
IMDX is expected to report earnings on Aug 06, 2026.
NEPH is expected to report earnings on Aug 12, 2026.
Industries' Descriptions
@Medical Specialties (-3.19% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
@Pharmaceuticals: Other (-2.39% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
| IMDX | NEPH | IMDX / NEPH | |
| Capitalization | 149M | 39M | 382% |
| EBITDA | -45.4M | 868K | -5,231% |
| Gain YTD | -38.800 | -26.434 | 147% |
| P/E Ratio | N/A | 51.29 | - |
| Revenue | 1.95M | 19.1M | 10% |
| Total Cash | 28.2M | 4.02M | 702% |
| Total Debt | 3.07M | 968K | 317% |
IMDX | NEPH | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 72 | 24 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 84 Overvalued | 59 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 79 | |
PRICE GROWTH RATING 1..100 | 43 | 48 | |
P/E GROWTH RATING 1..100 | 100 | 41 | |
SEASONALITY SCORE 1..100 | n/a | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
NEPH's Valuation (59) in the null industry is in the same range as IMDX (84) in the Medical Specialties industry. This means that NEPH’s stock grew similarly to IMDX’s over the last 12 months.
NEPH's Profit vs Risk Rating (100) in the null industry is in the same range as IMDX (100) in the Medical Specialties industry. This means that NEPH’s stock grew similarly to IMDX’s over the last 12 months.
NEPH's SMR Rating (79) in the null industry is in the same range as IMDX (100) in the Medical Specialties industry. This means that NEPH’s stock grew similarly to IMDX’s over the last 12 months.
IMDX's Price Growth Rating (43) in the Medical Specialties industry is in the same range as NEPH (48) in the null industry. This means that IMDX’s stock grew similarly to NEPH’s over the last 12 months.
NEPH's P/E Growth Rating (41) in the null industry is somewhat better than the same rating for IMDX (100) in the Medical Specialties industry. This means that NEPH’s stock grew somewhat faster than IMDX’s over the last 12 months.
| IMDX | NEPH | |
|---|---|---|
| RSI ODDS (%) | N/A | N/A |
| Stochastic ODDS (%) | 1 day ago 89% | 1 day ago 79% |
| Momentum ODDS (%) | 1 day ago 90% | 1 day ago 84% |
| MACD ODDS (%) | 1 day ago 90% | 1 day ago 77% |
| TrendWeek ODDS (%) | 1 day ago 90% | 1 day ago 78% |
| TrendMonth ODDS (%) | 1 day ago 90% | 1 day ago 81% |
| Advances ODDS (%) | 4 days ago 78% | 4 days ago 75% |
| Declines ODDS (%) | 21 days ago 90% | N/A |
| BollingerBands ODDS (%) | 1 day ago 85% | 1 day ago 90% |
| Aroon ODDS (%) | 1 day ago 90% | 1 day ago 90% |
Advertisement
IMDX and
Correlation & Price change
A.I.dvisor indicates that over the last year, IMDX has been loosely correlated with STRRP. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if IMDX jumps, then STRRP could also see price increases.
| Ticker / NAME | Correlation To IMDX | 1D Price Change % | ||
|---|---|---|---|---|
| IMDX | 100% | -9.65% | ||
| STRRP - IMDX | 37% Loosely correlated | +0.70% | ||
| FATE - IMDX | 31% Poorly correlated | -2.58% | ||
| NEPH - IMDX | 30% Poorly correlated | -1.10% | ||
| GOSS - IMDX | 29% Poorly correlated | -15.09% | ||
| BMRN - IMDX | 29% Poorly correlated | +0.14% | ||
More | ||||
NEPH and
Correlation & Price change
A.I.dvisor indicates that over the last year, NEPH has been loosely correlated with SGHT. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if NEPH jumps, then SGHT could also see price increases.
| Ticker / NAME | Correlation To NEPH | 1D Price Change % | ||
|---|---|---|---|---|
| NEPH | 100% | -1.10% | ||
| SGHT - NEPH | 34% Loosely correlated | +0.38% | ||
| IMDX - NEPH | 31% Poorly correlated | -9.65% | ||
| GH - NEPH | 28% Poorly correlated | -1.03% | ||
| LUCY - NEPH | 27% Poorly correlated | -2.78% | ||
| AZTA - NEPH | 25% Poorly correlated | +2.72% | ||
More | ||||